Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

NCT01508702 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

214

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout

Interventions

DRUG: lesinurad
DRUG: Placebo

Sponsor

Ardea Biosciences, Inc.